Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04358003 · ClinicalTrials.gov registry record · NA
Plasma Adsorption in Patients With Confirmed COVID-19
A NA study, sponsored by Marker Therapeutics.
- Completed
- Registry status
- NA
- Development phase
- 107
- Enrollment target
NCT04358003 is a NA study that has completed, run by Marker Therapeutics. The registered enrollment target is 107 participants.
The verdict
NCT04358003, a NA study, has completed, sponsored by Marker Therapeutics.
- COMPLETED
- Registry status
- NA
- Development phase
- 107 participants
- Enrollment target
Study Summary
To characterize the ability of the D2000 Cartridge in combination with the Optia SPD Protocol to reduce the morbidity and mortality associated with SARS-CoV-2 infection in patients admitted to the ICU.
Interventions
- DEVICE Marker Therapeutics D2000 Cartridge (D2000) for use with the Spectra Optia® Apheresis System (Optia SPD Protocol)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 107 participants |
| Start Date | 2020-05-20 |
| Est. Completion | 2022-04-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04358003
The ClinicalTrials.gov registry entry for NCT04358003 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 107 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Marker Therapeutics, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Marker Therapeutics D2000 Cartridge (D2000) for use with the Spectra Optia® Apheresis System (Optia SPD Protocol) is the first listed.
NCT04358003 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04358003 about?
NCT04358003 is a clinical study titled "Plasma Adsorption in Patients With Confirmed COVID-19". To characterize the ability of the D2000 Cartridge in combination with the Optia SPD Protocol to reduce the morbidity and mortality associated with SARS-CoV-2 infection in patients admitted to the ICU.
What is the current status of trial NCT04358003?
This trial is currently completed. It is a NA study. The enrollment target is 107 participants. The study started on 2020-05-20. Estimated completion is 2022-04-01.
What interventions are being tested in trial NCT04358003?
The interventions under investigation include: Marker Therapeutics D2000 Cartridge (D2000) for use with the Spectra Optia® Apheresis System (Optia SPD Protocol) (DEVICE).
Who is sponsoring clinical trial NCT04358003?
This trial is sponsored by Marker Therapeutics, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.